Posted by Michael Wonder on 21 Jan 2023
RemeGen announces two indications for anti-HER2 antibody drug conjugate disitamab vedotin included in China's National Reimbursement Drug List for 2023
20 January 2023 - RemeGen is pleased to announce that as of 18 January 2023, two indications for the Company's proprietary anti-HER2 antibody drug conjugate, disitamab vedotin, have been successfully included in the new version of national reimbursement drug list in China.
Specifically, the indication of HER2 expressing patients with locally advanced or metastatic urothelial carcinoma, was first included in the new national reimbursement drug list this year.
